A geldanamycin analog for conjugation to a monoclonal antibody

17-GMB-APA-GA is a maleimido derivative of geldanamycin that enables the conjugation of GA to a monoclonal antibody (mAb) such as Herceptin, the first mAb approved for therapy of solid tumors. This geldanamycin immunoconjugate induces less systemic toxicity than GA by being selectively delivered into malignant cells, a property conferred by the mAb that acts as the targeting vehicle. NCI has reported that Herceptin-GA conjugates deliver a more potent selective cytotoxic impact to Her2-overexpressing tumors than Herceptin alone [1]. To prepare such conjugates, GA is modified to introduce a latent primary amine [2]. After deprotection, this primary amine provides a site for introduction of a maleimide group that enables linkage to proteins.


Formula: C39H53N5O11

Molecular weight: 768

Solubility: DMSO (10 mg/ml)


- 1 mg


1. Mandler R. et al., 2004. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res. 64(4):1460-7.
2. Mandler R. et al., 2002. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates. Bioconjug Chem. 13(4):786-91.



Cat. Codegmbapa-ga
Unit Size1 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".